Lupin gains after subsidiary launches Tri-Lo-Marzia Tablets in US

Lupin rose 0.35% to Rs 1,760.30 at 09:20 IST on BSE after the company announced that its US subsidiary Lupin Pharmaceutical Inc. has launched its Tri-Lo-Marzia Tablets in the US.

Meanwhile, the BSE Sensex was down 287.68 points, or 1.13% to 25,102.69

On BSE, so far 5,049 shares were traded in the counter, compared with an average volume of 94,859 shares in the past one quarter. The stock hit a high of Rs 1,769.35 and a low of Rs 1,742.60 so far during the day. The stock had hit a record high of Rs 2,127 on 6 October 2015. The stock had hit a 52-week low of Rs 1,364.60 on 7 January 2015.

The large-cap company has an equity capital of Rs 90.10 crore. Face value per share is Rs 2.

Lupin after market hours yesterday, 6 January 2016 announced that its US subsidiary Lupin Pharmaceutical Inc. has launched in the US its Tri-Lo-Marzia Tablets (Norgestimate and Ethinyl Estradiol Tablets USP, 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg) after receiving approval from the United States Food and Drug Administration (FDA) to market a generic equivalent of Janssen Pharmaceuticals Inc. (Janssen) Ortho Tri-Cyclen Lo Tablets, (Norgestimate and Ethinyl Estradiol Tablets USP, 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg). Lupin's Tri-Lo-Marzia Tablets are the AB rated generic equivalent of Janssen Ortho Tri-Cyclen Lo Tablets. It is indicated for use by women to prevent pregnancy. Ortho Tri-Cyclen Lo Tablets had annual sales of $488.4 million in the US as per IMS MAT September 2015 data. The product represents Lupin's 16th oral contraceptive launch in the US.

Lupin's consolidated net profit dropped 35.1% to Rs 408.84 crore on 2% rise in net sales to Rs 3178.29 crore in Q2 September 2015 over Q2 September 2014.

Lupin is a pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Powered by Capital Market - Live News